Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection

Citation
O. Istre et B. Trolle, Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection, FERT STERIL, 76(2), 2001, pp. 304-309
Citations number
14
Categorie Soggetti
Reproductive Medicine","da verificare
Journal title
FERTILITY AND STERILITY
ISSN journal
00150282 → ACNP
Volume
76
Issue
2
Year of publication
2001
Pages
304 - 309
Database
ISI
SICI code
0015-0282(200108)76:2<304:TOMWTL>2.0.ZU;2-F
Abstract
Objective: Treatment of menorrhagia with levonorgestrel intrauterine system (LNG IUS) and transcervical resection. Design: An open, therapeutic, randomized study. Setting: Central county hospital specializing in hysteroscopy. Patient(s): Two parallel groups of 30 subjects each. Intervention(s): Thirty patients had a LNG IUS inserted within the first 7 days of menses; 29 patients underwent endometrial resection. Main Outcome Measure(s): A 12-month follow-up of menstrual blood loss and a dverse events were evaluated. Result(s): LNG IUS group: 13 patients reported one or more pelvic adverse e vents, bleeding disorders (n = 6), abdominal pain (n = 4), breast tendernes s (n = 3), headache, acne (n = 2), and mood changes (n = 1). Six patients d iscontinued treatment because of irregular bleeding (n = 3), pain (n = 2), and acne (n = 1). In both groups, general feeling of genital health increas ed with Visual Analogue Scale score. Nine patients reported adverse events. This included pelvic pain indicating inflammation (n 4), bleeding (n = 3), vaginitis (n = 1), and ulceration (n. = 1). Treatment success at 12 months was achieved in 20 (67%) of the 30 patients in the LNG IUS group and in 26 (90%) of the 29 patients in the transcervical resection group. Adverse eve nts were more often reported in the LNG IUS group. Conclusion(s): Both treatments effectively reduced the menstrual blood loss . Furthermore, the LNG IUS treatment is reversible and has no operative haz ards. (C) 2001 by American Society for Reproductive Medicine.